Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
4/24/2003
 
First Published:
7/1/2002
1.
Phase II Study of Epothilone B in Patients With Advanced Renal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0202045
NOVARTIS-CEP0906A2207, NCI-G02-2091, NCT00041002
2.
Patupilone Activity in Advanced/Metastatic Hepatocellular Carcinoma
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
Pharmaceutical / Industry
CEPO906A2213
NCT00273312
3.
EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 to 85
Pharmaceutical / Industry
CEPO906A2203
NCT00035100
4.
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
20 and over
Pharmaceutical / Industry
CEPO906A1103
NCT00412789
5.
Evaluate the Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Biomarker/Laboratory analysis, Treatment
Closed
18 and over
Pharmaceutical / Industry
CEPO906A2120
NCT00448396
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute